Lipid‐lowering therapy to prevent cardiovascular disease and practical aspects of migraine management were among the topics presented at continuing professional development sessions during the Best Practice London conference held in March 2023. Steve Titmarsh reports.
{"title":"Best Practice London: focus on lipid and migraine management","authors":"S. Titmarsh","doi":"10.1002/psb.2080","DOIUrl":"https://doi.org/10.1002/psb.2080","url":null,"abstract":"Lipid‐lowering therapy to prevent cardiovascular disease and practical aspects of migraine management were among the topics presented at continuing professional development sessions during the Best Practice London conference held in March 2023. Steve Titmarsh reports.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86064222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Liver function tests (LFTs) are useful blood tests to help identify liver disease, but their interpretation can be challenging. Part 1 in this two‐part series on understanding LFTs discusses who should be screened, the advantages and limitations of the main LFTs, and how LFTs should be interpreted.
{"title":"Understanding liver function tests: part 1","authors":"G. Parsons","doi":"10.1002/psb.2079","DOIUrl":"https://doi.org/10.1002/psb.2079","url":null,"abstract":"Liver function tests (LFTs) are useful blood tests to help identify liver disease, but their interpretation can be challenging. Part 1 in this two‐part series on understanding LFTs discusses who should be screened, the advantages and limitations of the main LFTs, and how LFTs should be interpreted.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"82 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73398789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
New effective treatments for Alzheimer's disease have eluded researchers for many years, but promising pharmacotherapies may at last be approaching clinical approval. This article examines some of these new treatments, their modes of action and the practicalities of implementation once they reach the market.
{"title":"Is the NHS ready for new Alzheimer's disease treatments?","authors":"M. Greener","doi":"10.1002/psb.2078","DOIUrl":"https://doi.org/10.1002/psb.2078","url":null,"abstract":"New effective treatments for Alzheimer's disease have eluded researchers for many years, but promising pharmacotherapies may at last be approaching clinical approval. This article examines some of these new treatments, their modes of action and the practicalities of implementation once they reach the market.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81326120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tirzepatide (Mounjaro) is a dual GLP‐1/GIP receptor agonist for the treatment of type 2 diabetes in adults. This article discusses its administration, clinical trial efficacy and adverse effects.
{"title":"Tirzepatide for the treatment of adults with type 2 diabetes","authors":"S. Chaplin","doi":"10.1002/psb.2081","DOIUrl":"https://doi.org/10.1002/psb.2081","url":null,"abstract":"Tirzepatide (Mounjaro) is a dual GLP‐1/GIP receptor agonist for the treatment of type 2 diabetes in adults. This article discusses its administration, clinical trial efficacy and adverse effects.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"308 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85717957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Monoamine oxidase inhibitors (MAOIs) are generally only initiated by specialists because of safety concerns, making GPs more wary of these medicines. This article discusses the important side‐effects and interactions of MAOIs and how these can be minimised, and explains why MAOI prescribing may be safer than we are led to believe.
{"title":"MAOI prescribing: separating misconceptions from reality","authors":"Aisling Molloy","doi":"10.1002/psb.2077","DOIUrl":"https://doi.org/10.1002/psb.2077","url":null,"abstract":"Monoamine oxidase inhibitors (MAOIs) are generally only initiated by specialists because of safety concerns, making GPs more wary of these medicines. This article discusses the important side‐effects and interactions of MAOIs and how these can be minimised, and explains why MAOI prescribing may be safer than we are led to believe.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73282457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NICE has recently updated its guideline on the management of diabetes in children and young people (NG18), with new recommendations on monitoring and treating type 2 diabetes in young patients. This article summarises the main changes in the latest update.
{"title":"Diagnosis and management of type 2 diabetes in children","authors":"S. Chaplin","doi":"10.1002/psb.2082","DOIUrl":"https://doi.org/10.1002/psb.2082","url":null,"abstract":"NICE has recently updated its guideline on the management of diabetes in children and young people (NG18), with new recommendations on monitoring and treating type 2 diabetes in young patients. This article summarises the main changes in the latest update.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"117 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77039808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chronotherapy is a promising approach to drug dosing that optimises the timing of administration to synchronise with our circadian rhythms. This article discusses how researchers are finding ways to utilise chronotherapy's potential to increase the efficacy and safety of various drug therapies.
{"title":"Update on chronotherapy: it's about time","authors":"M. Greener","doi":"10.1002/psb.2070","DOIUrl":"https://doi.org/10.1002/psb.2070","url":null,"abstract":"Chronotherapy is a promising approach to drug dosing that optimises the timing of administration to synchronise with our circadian rhythms. This article discusses how researchers are finding ways to utilise chronotherapy's potential to increase the efficacy and safety of various drug therapies.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87879730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：